Payment overview · 2025
General Payments
$937.18
42 reported records · 15 companies
Healthcare provider profile · identity verified
Agnes Ubani, MD
Allopathic & Osteopathic Physicians|Family Medicine · TEMPLE TERRACE, FL · NPI 1285702894
Verified facts
What the public records show
CMS Open Payments records show Agnes Ubani, MD received $937.18 in general payments during 2025 across 42 reported records.
MERZ NORTH AMERICA, INC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $264.04 | 28.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $249.83 | 26.7% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.37 | 7.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.61 | 5.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.71 | 5.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $40.57 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.63 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.53 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.39 | 2.7% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $25.21 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.22 | 2.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.21 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.75 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.39 | 1.8% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.72 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $937.18 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $264.04 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $204.21 | 16 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $204.21 | 16 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.37 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.61 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.92 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.63 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 231 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 258 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
231 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
231 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
182 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
258 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1039 | 320 |
| Amlodipine Besylate | Amlodipine Besylate | 793 | 229 |
| Gabapentin | Gabapentin | 527 | 156 |
| Alprazolam | Alprazolam | 488 | 103 |
| Losartan Potassium | Losartan Potassium | 429 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 99 |
| Furosemide | Furosemide | 364 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 352 | 121 |
| Metformin Hcl | Metformin Hcl | 348 | 117 |
| Lisinopril | Lisinopril | 316 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 105 |
| Potassium Chloride | Potassium Chloride | 311 | 99 |
| Nifedipine Er | Nifedipine | 278 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 84 |
| Meloxicam | Meloxicam | 262 | 83 |
| Ozempic | Semaglutide | 258 | 44 |
| Tramadol Hcl | Tramadol Hcl | 257 | 86 |
| Omeprazole | Omeprazole | 249 | 82 |
| Ibuprofen | Ibuprofen | 246 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 233 | 44 |
| Azithromycin | Azithromycin | 232 | 180 |
| Jardiance | Empagliflozin | 231 | 59 |
| Famotidine | Famotidine | 222 | 64 |
| Carvedilol | Carvedilol | 221 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 216 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 190 | 53 |
| Montelukast Sodium | Montelukast Sodium | 187 | 57 |
| Mounjaro | Tirzepatide | 182 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 49 |
| Methylprednisolone | Methylprednisolone | 171 | 128 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 170 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 46 |
| Eliquis | Apixaban | 162 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 159 | 113 |
| Glimepiride | Glimepiride | 159 | 48 |
| Trazodone Hcl | Trazodone Hcl | 159 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 151 | 69 |
| Fluconazole | Fluconazole | 151 | 71 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 151 | 48 |
| Clonidine Hcl | Clonidine Hcl | 145 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 138 | 110 |
| Ezetimibe | Ezetimibe | 134 | 54 |
| Azelastine Hcl | Azelastine Hcl | 129 | 82 |
| Prednisone | Prednisone | 126 | 63 |
| Januvia | Sitagliptin Phosphate | 120 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 54 |
| Lorazepam | Lorazepam | 117 | 26 |
| Farxiga | Dapagliflozin Propanediol | 116 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 36 |
| Atenolol | Atenolol | 112 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 34 |
| Simvastatin | Simvastatin | 106 | 34 |
| Spironolactone | Spironolactone | 102 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 98 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 32 |
| Donepezil Hcl | Donepezil Hcl | 97 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 32 |
| Alendronate Sodium | Alendronate Sodium | 96 | 29 |
| Allopurinol | Allopurinol | 96 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 30 |
| Temazepam | Temazepam | 91 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 90 | 28 |
| Celecoxib | Celecoxib | 88 | 21 |
| Trulicity | Dulaglutide | 88 | 17 |
| Amoxicillin | Amoxicillin | 85 | 66 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 18 |
| Sertraline Hcl | Sertraline Hcl | 83 | 25 |
| Bumetanide | Bumetanide | 82 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 27 |
| Risperidone | Risperidone | 78 | 16 |
| Irbesartan | Irbesartan | 77 | 25 |
| Buspirone Hcl | Buspirone Hcl | 76 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 66 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 75 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 21 |
| Hydrocortisone | Hydrocortisone | 74 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 11 |
| Baclofen | Baclofen | 69 | 25 |
| Ketoconazole | Ketoconazole | 69 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 18 |
| Acyclovir | Acyclovir | 65 | 29 |
| Cephalexin | Cephalexin | 65 | 50 |
| Diazepam | Diazepam | 62 | 14 |
| Clonazepam | Clonazepam | 61 | 18 |
| Nitroglycerin | Nitroglycerin | 61 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 59 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 57 | 12 |
| Benazepril Hcl | Benazepril Hcl | 56 | 15 |
| Metronidazole | Metronidazole | 55 | 35 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 54 | 12 |
| Nystatin | Nystatin | 53 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 19 |
| Pregabalin | Pregabalin | 50 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 31 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 49 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 47 | 13 |
| Linzess | Linaclotide | 46 | 14 |
| Topiramate | Topiramate | 46 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 46 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 23 |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Mirtazapine | Mirtazapine | 44 | 18 |
| Valsartan | Valsartan | 44 | 17 |
| Verapamil Er | Verapamil Hcl | 44 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 14 |
| Methotrexate | Methotrexate Sodium | 43 | 12 |
| Sucralfate | Sucralfate | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 39 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 20 |
| Glipizide | Glipizide | 37 | suppressed |
| Minoxidil | Minoxidil | 37 | 11 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 14 |
| Ondansetron Odt | Ondansetron | 34 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Dexamethasone | Dexamethasone | 32 | 27 |
| Methocarbamol | Methocarbamol | 32 | 22 |
| Lactulose | Lactulose | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | 15 |
| Clonidine | Clonidine | 26 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Felodipine Er | Felodipine | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 18 |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Ramipril | Ramipril | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Premarin | Estrogens, Conjugated | 16 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tegretol Xr | Carbamazepine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $937.18 · 42 records | MERZ NORTH AMERICA, INC. | CAPLYTA, CAPVAXIVE, CREON, FARXIGA, FUROSCIX, ImmunoCAP, JARDIANCE, Kerendia, Korlym, Natroba, Ozempic, PIFELTRO, QULIPTA, Rybelsus, Spinosad, TRELEGY ELLIPTA, TZIELD, UBRELVY, Wegovy, Xeomin | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error